RUNIMOTAMAB
UNII F8Z9VSZ0K1

Substance Identification & Data

This profile provides standardized clinical and technical data for Runimotamab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) F8Z9VSZ0K1.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2361325-98-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

F8Z9VSZ0K1

CAS Registry Number

2361325-98-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

RUNIMOTAMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C156705

National Cancer Institute reference terminology for clinical and research data.

INN ID

11496

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-194

Identifier assigned by the United States Adopted Names Council.

Substance Type

RUNIMOTAMAB

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Runimotamab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

RUNIMOTAMAB

Common Names & Synonyms

ANTI-HER2/CD3 TDB

HER2/CD3 TDB

IMMUNOGLOBULIN G1 (300-GLYCINE,369-TRYPTOPHAN), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER2) (HUMAN MONOCLONAL KTRC5520 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL KTRC5520 .KAPPA.-CHAIN, (229->228'),(232->231')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (299-GLYCINE,368-SERINE,370-ALANINE,409-VALINE) ANTI-(HUMAN CD3 ANTIGEN) (HUMAN MONOCLONAL HTHR4765 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN MONOCLONAL HTHR4765 .KAPPA.-CHAIN

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINE PROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185CERBB2, NEU, CD340)) AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), MONOCLONAL ANTIBODY, BISPECIFIC; GAMMA1 HEAVY CHAIN ANTI- ERBB2 (1-450) (VH ANTI-ERBB2 (HOMO SAPIENS IGHV3-66*01 (81.6%)- (IGHD)-IGHJ4*01 (100%)) CDR-IMGT (8.8.13) (26-33.51-58.97-109) (1-120)- HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1, G1V30 CH2 G84.4, G1V32 CH3 W22 (CH1 R120>K (217) (121-218), HINGE 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344- 448), CHS (449-450)) (121-450)), (223-214')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-ERBB2 (1'-214') (V-KAPPA ANTI-ERBB2 (HOMO SAPIENS IGKV1-39*01 (86.3%)-IGKJ1*01 (100%)) CDR-IMGT (6.3.9) (27-32.50-52.89-97) (1'-107')- HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); GAMMA1 HEAVY CHAIN ANTI-CD3E (1''-449'') (VH ANTI-CD3E (MUS MUSCULUS IGHV1-66*01 (82.7%)-(IGHD)-IGHJ2*01 (86.7%)/HOMO SAPIENS ANTI-CD3E IGHV1-3*01 (82.7%)-(IGHD)-IGHJ4*01 (100%)) CDR-IMGT (8.8.12) (26- 33.51-58.97-108) (1''-119'')-HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1, G1V30 CH2 G84.4, G1V33 CH3 S22, A24, V86 (CH1 R120>K (216) (120''-217''), HINGE 1-15 (218''-232''), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343''-447''), CHS (448''-449'') (120''-449'')), (222''-219''')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI- CD3E (1'''-219''') (V-KAPPA ANTI-CD3E (HOMO SAPIENS IGKV4-1*01 (91.8%)- IGKJ1*01 (100%)) CDR-IMGT (12.3.8) (27-38.56-58.95-102) (1'''-112''')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (158), V101 (196) (113'''-219''')); DIMER (229-228'':232-231'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, NON-GLYCOSYLATED

RUNIMOTAMAB [USAN]

Runimotamab [WHO-DD]

runimotamab [INN]